UPDATE: Jefferies Initiates Lexicon Pharmaceuticals at Buy on Class-Leading SGLT Inhibitor

In a report published on Wednesday, Jefferies analyst Thomas Wei initiated coverage on Lexicon Pharmaceuticals (NASDAQ: LXRX ) with a Buy Rating and a price target of $3.50. In the report, Jefferies stated, "We believe investors have underestimated the potential for SGLTs to show a CV outcomes benefit. We see